Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1024476 | 0.82 | TSHR (0.34) | SIGMAR1SMN1; SMN2TSHRNPC1LMNA | |
| SCHEMBL4465934 | 0.76 | BRD4 (0.34) | SMN1; SMN2NPC1LMNATP53RAB9A | |
| SCHEMBL4198923 | 0.74 | PTAFR (0.34) | SMN1; SMN2KDM4EALDH1A1HPGDHTT | |
| SCHEMBL6231893 | 0.73 | PTAFR (0.37) | SMN1; SMN2TSHRNPC1LMNATP53 | |
| SCHEMBL690593 | 0.73 | TSHR (0.36) | SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL14645947 | 0.70 | RXRB (0.34) | — | |
| SCHEMBL27663765 | 0.67 | TSHR (0.36) | SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL1029393 | 0.66 | — | — | |
| SCHEMBL1032918 | 0.66 | TSHR (0.32) | SMN1; SMN2TSHRNPC1LMNATP53 | |
| SCHEMBL25456880 | 0.65 | KDM4E (0.36) | SMN1; SMN2KDM4EALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1455938-B1 | ORGANOMETALLIC TRANSITION METAL COMPOUND, BISCYCLOPENTADIENYL LIGAND SYSTEM, CATALYST SYSTEM AND PREPARATION OF POLYOLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-7109278-B2 | Organometallic transition metal compound, biscyclopentadienyl ligand system, catalyst system and preparation of polyolefins | BASELL POLYOLEFINE GMBH (DE) | 2006-09-19 | — | — | US | disclosed |
| US-20040260107-A1 | Organometallic transition metal compound, biscyclopentadienyl ligand system, catalyst system and preparation of polyolefins | EQUISTAR CHEMICALS, LP | 2004-12-23 | — | — | US | disclosed |
| EP-1455938-A1 | ORGANOMETALLIC TRANSITION METAL COMPOUND, BISCYCLOPENTADIENYL LIGAND SYSTEM, CATALYST SYSTEM AND PREPARATION OF POLYOLEFINS | Basell Polyolefine GmbH (DE) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003045551-A1 | ORGANOMETALLIC TRANSITION METAL COMPOUND, BISCYCLOPENTADIENYL LIGAND SYSTEM, CATALYST SYSTEM AND PREPARATION OF POLYOLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040260107-A1 | Organometallic transition metal compound, biscyclopentadienyl ligand system, catalyst system and preparation of polyolefins | SOD1, SCO2, SOD3 | SIGMAR1 417/4885TMEM97 2753/4885SMN1; SMN2 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.